Synergys Awarded NCI Grant to Develop SYN001 for Triple-negative Breast Cancer
News
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded Synergys Biotherapeutics a grant to support the development of its antibody fusion molecule SYN001 for the treatment of triple negative breast cancer ... Read more